about
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapyThe t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceMapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.Molecular cytogenetic characterization of proximal-type epithelioid sarcoma.Gender disparities in the tumor genetics and clinical outcome of multiple myelomaA novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.Deletions of CDKN2C in multiple myeloma: biological and clinical implicationsPDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.Frequent upregulation of MYC in plasma cell leukemia.Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone.Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma.Activity of sunitinib in extraskeletal myxoid chondrosarcomaGene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaDeletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myelomaMolecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell CarcinomaHER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile ChangingSYT-SSX Fusion Transcripts and Epithelial Differentiation in Synovial SarcomaHerceptin® plus chemotherapy in relapsed and/or metastatic salivary gland cancerMyogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal LiposarcomaThe clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapyA compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueOpposite deletions/duplications of the X chromosome: two novel reciprocal rearrangementsImmunophenotypic and genotypic analysis of a case of primary peripheral primitive neuroectodermal tumour (pPNET) of the urinary bladderHeterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma
P50
Q33272734-2084D833-9ABA-4A65-AC99-8FDC8BFA559AQ33416940-1EB297BF-A4D3-44D6-AFCE-394F8CD3F60DQ33952861-77C6111B-F6F1-4821-AF74-4CE98E817D6EQ34223730-1687B6B1-045C-405E-9B3B-7CF19624639EQ35873435-DE2C4A2A-48B7-4061-A0EF-F13CCACB0E15Q35984694-9069EAFC-E9F2-4DCA-A3B0-3B764C119D91Q35984702-E49E9A55-32FC-4AE1-8942-72E025AE3656Q36272148-5DCBB01C-C112-4CCC-8BFC-90EDE9CA7B2EQ37565298-5AF5F0D7-4DBB-4B40-A0CD-91DD0509A722Q38873696-9C3F4244-C2C9-4439-BA6B-F4B95C96047FQ39409643-CB18C6F6-B408-440D-BF77-96DC73C31BC2Q39933622-9488E612-1F87-48BA-AB63-DC0A5A1D7F22Q40351643-B92ADE45-AD37-43AE-8136-F7635DED19B0Q40485928-0EE1740A-0316-4537-B383-8FF4DE93DFDDQ42434702-928E6DF0-D430-4C3D-81DE-95286B7544E7Q47934970-E54305D2-74C7-4CBE-808E-012BB335A556Q48031054-E10757FB-C6FE-45DD-808A-5371802F6AACQ48181717-8E45E246-E6D6-455E-8BAA-124D6F3E79DEQ51694181-F0451A4A-C7C2-4CEC-B4E1-A579430D5E86Q53857277-B3CA36F2-B13C-43FF-908E-F2E99BED12FCQ54253499-8331C09F-8417-4A88-8D29-21D62936F804Q54301350-73D4ED03-7FBA-41CD-8CBB-1EFCD5889EE0Q54661269-AD0A2FD1-799A-4829-9324-F1C651D90A38Q55021635-05C1675A-D786-41E7-AEF4-6DAA8F56408EQ56974103-AC4DA2E8-B522-4892-80B8-8922428D3323Q58455724-48FB44A2-046B-4627-8A25-2FF15EA17587Q58455735-60D27756-3825-42BC-A1E4-3702C5F6390FQ58813367-51E66F45-54CF-4FAF-99C4-E786D188D419Q58813403-C5370C1C-5EEE-4A1B-A813-5FFB4B31D59EQ58813430-0FD32BE4-8A12-47CC-9678-EE5D206B26E6Q60637536-EF60A210-C19D-47AA-A960-103060E45E2BQ61040877-45A50EBF-FC87-4FDE-807B-34A2D28E47A0Q61905658-2A95E453-94F6-4B9E-911E-140179494D42Q61905667-05876BFE-6F48-4261-ACC6-BE974D64F312Q73540772-7EB324CC-8014-4360-957C-B61C2AE4E407Q77792172-B59C752C-A7C7-4D47-BF51-5DC3211A721FQ82766788-3A0011D9-7955-462E-8001-92759351BAE5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gian Paolo Dagrada
@ast
Gian Paolo Dagrada
@en
Gian Paolo Dagrada
@es
Gian Paolo Dagrada
@nl
Gian Paolo Dagrada
@sl
type
label
Gian Paolo Dagrada
@ast
Gian Paolo Dagrada
@en
Gian Paolo Dagrada
@es
Gian Paolo Dagrada
@nl
Gian Paolo Dagrada
@sl
prefLabel
Gian Paolo Dagrada
@ast
Gian Paolo Dagrada
@en
Gian Paolo Dagrada
@es
Gian Paolo Dagrada
@nl
Gian Paolo Dagrada
@sl
P1053
D-6927-2017
P106
P1153
12792543100
P21
P31
P3829
P496
0000-0002-6743-1935